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Abstract
Social media marketing is evolving rapidly and gaining popularity within academia 
and firms. This chapter highlights the major challenges posed by social media to the 
pharmaceutical industry, assessing the presence of major pharmaceutical firms on social 
media platforms such as Facebook, Twitter, and YouTube and characterizing their digital 
engagement strategies. This study gathered data from the top 20 pharmaceutical compa-
nies’ official websites, Facebook, Twitter, and YouTube accounts and examined variables 
such as Internet presence, engagement, fans/followers, and network structure. Findings 
from this study show that not all pharmaceutical firms are present on social media, and 
some platforms are used more than others. Notably, the digital engagement strategies 
varied between the analyzed social media platforms and remained similar on the two 
periods. Results also show that the level of engagement assessed was not associated with 
firm size. In several firms, the communication was mostly directed to the general public. 
Depending on the company, country-based communities were found. This work can be 
of interest to practitioners aiming to compare and assess their digital activity. It could 
also assist future researchers focusing on pharmaceutical social media marketing activ-
ity, since few researchers have analyzed this using more than one social networking site.
Keywords: communication, social media, pharmaceutical, Facebook, Twitter, YouTube
1. Introduction
Pharmaceutical firms are increasingly facing competitive, regulatory, and community pres-
sures. For decades, pharmaceutical firms tried using different types of promotions to affect 
physicians’ prescribing behavior. It has now evolved to a point where it has been often said that 
the leading firms were spending more on marketing than on research and development [1]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
This led to misconceptions related to pharmaceutical marketing practices and induced the 
need to unveil the true meaning of pharmaceutical marketing. Pharmaceutical marketing, as 
a sub branch of marketing, evolved over the years from a more product-oriented strategy to a 
consumer-oriented strategy, following global trends [2].
Back in 1994, Levy [3] stated “pharmaceutical marketing is the last element of an informa-
tion continuum, where research concepts are transformed into practical therapeutic tools and 
where information is progressively layered and made more useful to the health care system” 
(p. 327). His definition emphasizes the value of information flow. In the last two decades, 
there has been a major shift from traditional media to digital media, changing profoundly the 
way information flows. The race for information access turned patients, physicians, and all 
other healthcare stakeholders more demanding. In order to reduce these pressures and estab-
lish a long-term relationship with the different stakeholders, pharmaceutical firms need to fol-
low marketing trends and move on to digital communication channels, such as social media.
The emerging importance of social media in business organizations is raising the awareness 
of decision-makers toward this theme. An ongoing dialog on platforms such as Facebook, 
Twitter, and YouTube between firms and consumers impels the search for new management 
communication models. In response, this chapter analyzes the online posture of 20 major 
pharmaceutical firms. For this purpose, data were gathered directly from their official social 
media pages on Facebook, Twitter, and YouTube, and their performance online was analyzed.
This chapter is organized in the following manner. The next section summarizes the literature 
related to pharmaceutical marketing and social media. The third section presents empirical 
evidence from the pharmaceutical firms. The last section offers concluding remarks about 
these findings.
2. Theoretical framework
2.1. Pharmaceutical marketing
According to Fischer [4], pharmaceutical marketing practice is mutating. The author states 
that the major approach in the 90s and the beginning of 2000 was increasing the sales force, 
allowing intensified diffusion of scientific information. However, Fischer explains that spend-
ing on this approach is decreasing over time. Nowadays, pharmaceutical firms are aban-
doning the commercial model based on sales force and are adopting a more multifaceted 
communication strategy. Through Figure 1, Fischer explains this new strategy, composed of 
more channels of communication which interface with other stakeholders (e.g., patients, pay-
ers, healthcare organizations, and professionals), surpassing the almost unique channel based 
on communication with physicians. The spreading of communication channels and potential 
message recipients is perceived as a major trend in pharmaceutical marketing [4] (Figure 1).
2.1.1. Physician-oriented model
Pharmaceutical marketing budgets are largely being allocated to communicate with phy-
sicians [4]. According to Fischer [4], in this type of communication, pharmaceutical firms 
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are using personal selling through detailing directed to physicians that are general practi-
tioners, specialists, and hospital physicians. This regulation-dependent model can include 
(1) personal selling with discussion of a limited number of products, (2) delivery of some 
gifts and medication samples, (3) payment for meals, (4) conference-related issues, (5) 
financing of medical education and scientific projects, and (6) publicity in professional 
journals [4, 5].
Fischer states that methods like medical education and drug vigilance studies were devel-
oped to strengthen the relationship with physicians, and sometimes certain physicians can be 
provided with financial support from pharmaceutical firms if they are open to reporting their 
observations on patient trial studies associated with a promoted medication. Other channels, 
like direct mailing, allow pharmaceutical firms to deliver information about treatments or 
medicines to physicians [4].
Fischer [4] also considers that the traditional communication model is under fire from the rise 
of the Internet and other digital media. The author states that the study “Taking the Pulse® 
Europe” (p. 559), based on physicians’ behavior on the Internet, revealed that physicians are 
using the Internet to diversify the reach of their influence [4]. Fischer refers to the findings in 
this study showing that in the main European countries, 95% of physicians queried said that 
the Internet is useful in their professional practice, and for this reason it seems that pharma-
ceutical firms are walking along with physicians in this matter through the development of 
electronic strategies.
Figure 1. Pharmaceutical expenditure categories. Source: Adapted from [4], p. 560.
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According to several authors, physicians are open-minded toward technology adoption [6], 
allowing marketers to promote products through a new channel. It is clear that a growing 
number of physicians are networking online, and for that reason, pharmaceutical firms see 
the diffusion of information through online networking platforms as a priority [6, 7].
2.1.2. Patient/consumer-oriented model
There is a segment of pharmaceutical marketing that is being oriented toward patients/
consumers, but this direct activity is only accepted in a small group of countries, like New 
Zealand and the United States of America (USA) [4, 6]. However, in the European Union (EU), 
pharmaceutical firms can advertise directly to consumers when the advertised product is an 
over-the-counter (OTC) medicine [8].
Fischer [4] points out that direct to consumer (DTC) advertising uses channels like traditional 
media (e.g. print media, television, and radio) and digital media. When DTC advertising 
is not allowed in a country, companies use a below-the-line strategy (e.g. Public Relations 
campaigns associated with diseases and treatments) in order to influence patients/consum-
ers. Usually in this type of campaign, the branded medicine’s name is not promoted [4]. 
Nevertheless, the global reach of online platforms poses a challenge in this diversified world-
wide regulation setting [7, 9].
2.1.3. Model oriented at other stakeholders
Physicians and patients/consumers are not the only stakeholders targeted by pharmaceuti-
cal marketing [4]. Pharmacists, practice nurses, care providers, and informal caregivers are 
an audience that demands tailored communication strategies [4, 6]. Fischer [4] adds that the 
influence of these stakeholders as gatekeepers changes according to the type of medicine and 
healthcare structure. He provides an example with the healthcare business associated with 
diabetes. A major part of the budget is allocated to sales representatives in order to reach prac-
tice nurses and pharmacists since these healthcare professionals usually recommend devices 
that measure the blood glucose in people who suffer from this disease. Also, pharmaceutical 
firms allocate a percentage of their global budget into corporate public relations [4].
2.2. Pharmaceutical marketing challenges
Regulation is without a doubt a factor that distinguishes the pharmaceutical industry from 
other types of industries [10]. Regulatory activities are present in several pharmaceutical 
phases, like the approval of new medicines, medicine surveillance, production, and promo-
tion to physicians and consumers [7]. The approval of medicinal commercialization normally 
requires a guarantee of safety and efficacy of the product. It is supervised by the Food and 
Drug Administration (FDA) in the USA, by the European Medicines Agency in the EU (even 
though individual country members have their own regulatory bodies), and by the Ministry 
of Health and Welfare in Japan [11].
To Desiraju and Tran [10], the regulation of marketing practices is not uniform, and several 
differences exist between different areas of the world and between pharmaceutical marketing 
Digital Communication Management80
segments. For example, since 2006 in the USA, it is not possible for a pharmaceutical company 
to communicate off-label medication uses to a physician, but the physician does not have 
restrictions on employing off-label uses for any situation in which they think the drug will 
work [7]. In other areas of the world, detailing practices are restricted, as well as medication 
samples given to physicians [7].
DTC advertising regulation differs from country to country, following the legal constraints of 
each country or region [10]. For instance, while in the USA DTC advertising of prescription 
medicines is authorized, in the EU and Canada there are restrictions for its use [10].
There have been some developments regarding DTC advertising in the EU, but they did 
not have a happy ending due to European Commission propositions being rejected by the 
European Parliament [12]. However, the European Commission, along with other industries 
that have interests related to medicine, is continuously pressuring the adoption of DTC adver-
tising practices [12, 13].
In Canada, as DTC advertising is forbidden, pharmaceutical firms use two types of advertis-
ing allowed by regulatory institutions. The first type is associated with diseases, like “help-
seeking” advertisements where non-branded communications increase awareness about a 
certain illness and appeal to consumers to seek their physician’s guidance. The second type is 
a “reminder” advertisement that is a branded communication without any type of informa-
tion about the use of the medicine [12](p. 635).
On the other hand, with the Internet, several concerns arise since online advertising can reach 
places where DTC advertisement is not allowed [12]. As an example, in the GlaxoSmithKline 
blog or the AstraZeneca Facebook page, the information is directed only toward the USA, but 
users from all over the globe can access this information, surpassing any possible control [12]
(p. 635).
In terms of price regulation, there are also differences between nations [10]. It was also noted 
that price could be regulated through direct price impositions from governments, through 
price comparison between specific countries, or through pricing established by comparing 
medicines with an identical therapeutic category [7]. In some situations, governments can 
limit the global revenues of pharmaceutical companies. Countries like France, Italy, and Japan 
directly control prices, while countries like Germany, the Netherlands, and New Zealand 
manipulate reimbursements through price orientations, leading to changes in the amount 
that consumers have to pay [10].
Another challenge posed to this industry concerns the difference between branded medi-
cines and generic medicines. A generic medicine is a trustworthy replica of a branded 
medicine, which has an expired patent, and is commercialized under the name of the 
active ingredient from the patented medicine [14]. With the rise of generic medicines, 
pharmaceutical firms stopped the nerve-racking approval process necessary for biosimilar 
branded medicines, allowing them to save time and money while diminishing process risk 
[5, 10, 14].
For pharmaceutical firms with branded medicines, the key target is physicians, while con-
sumers and payers are vital targets for the development of brand loyalty and maintaining 
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favored status in a formulary [5, 9]. These authors state that generic medicines are similar 
to commodities, and therefore, the marketing mix is focused on price. They also affirm that 
the key target audience of generic medicines is different from the target audience of branded 
medicines. Even though physicians choose medication for their patients, pharmacies are the 
last intervention in the supply chain of medicines to patients. For this reason, they can choose 
the companies that supply their stock, making them the ultimate targets for pharmaceutical 
marketers of generic medicines [5]. However, both physicians and pharmacies can receive 
financial support from payers in order to encourage the use of generic medicines [7].
2.3. Social media marketing objectives and outcomes
Social networks have been a reality for about 15 years, changing the way companies and 
consumers interact, both in the digital domain and by transposing into the physical realm. 
Both companies and researchers recognize that social networks have facilitated the narrow-
ing of relations between companies and consumers, as they have provided consumers with 
an active voice and changed their behavior [15]. Therefore, the subject of social media is a 
high priority of discussion in the business world [16]. These authors argue that managers and 
marketers, as well as consultants, are forging new strategies aiming to increase companies’ 
profitability through social media (e.g. Wikipedia, YouTube, Facebook, and Twitter).
Before social media, the Internet already allowed limited user interaction [17]. Web 1.0 (the 
first generation of the web) was considered to be the “read-only web.” At this early stage, 
Internet users had limited interaction capability. Users were able to search and read infor-
mation created and shared by firms [17]. Regardless of this interaction constraint, Web 1.0 
revolutionized the access to information, since users could access countless diverse websites 
as information sources and were no longer limited to traditional vehicles like television trans-
missions or books [5]. Several of these websites appeared like simple brochures, whereas elec-
tronic commerce websites were similar to catalogs [5, 17].
The Web 2.0 was termed the “read-write web” [5, 17] since it allowed users to not only read 
but write content that could be shared to peers. This was the foundation of digital social inter-
action as we know it [17]. These authors recognize that with this iteration of the Web, online 
interaction was based on two-way communication. With Web 2.0, the sources of information 
considered relevant by consumers changed from firms to other online users [5]. These authors 
suggest that simultaneously with the rise of the Web 2.0, social network prototypes started to 
appear, providing new ways to facilitate interactions between people. These prototypes con-
verted with time into modern social media platforms (e.g. Twitter and Facebook) [5].
To Kotler and Keller [18] “social media [is] a mean for consumers to share text, images, audio, 
and video information with each other and with companies and vice versa, encouraging 
brand engagement at a deeper and broader level than before” (p. 291).
Kietzmann, Hermkens, McCarthy, and Silvestre [19] contend that social media allows interac-
tion between users based on seven functionalities: presence, sharing, conversation, identity, 
relationship, groups, and reputation.
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From a user perspective, social networking sites (SNSs) integrate several digital formats of 
user-generated content (UGC) such as “blogs, virtual communities, wikis, social networks, 
collaborative tagging, and sites that allow shared media files” [20].
To most users, these types of SNSs are attractive because they enable them to participate in an 
ongoing consumption-creation cycle; the content created and shared by some become infor-
mation sources for others, that can also be commented on, shared, and tagged [21].
From a brand perspective, the potential of social media lies not only in communication and 
sales, but also in persuasion [18]. Several researchers have pointed out the capability of elec-
tronic word of mouth (e-WoM) to influence peers’ purchasing decisions [22]. Still, not all 
shared content has a positive impact on brands; as it happens in non-digital contexts, negative 
messages are also spread. Thus, social media can provide marketers a channel to be present 
on the web, reinforcing brand awareness and notoriety, but it also presents several challenges 
that need to be taken into account, some which depend on marketers’ willingness to respond 
in an engaging manner to negative user comments [18].
Facebook presence has become a must for numerous companies, and Twitter can enhance 
business, even for small companies [18]. Social networks can leverage brand presence, brand 
awareness, and also reduce advertisement costs (especially important in fragile economic sit-
uations) [23]. However, it is important for companies to be aware of ethical matters (e.g. user 
privacy, spamming, publicity policies, data mining, and legal concerns).
2.4. Social media pharmaceutical marketing
Marketers are overwhelmed by performance promises related to new communications 
approaches and technologies. As noted by several authors, digital communication over social 
media with patients/consumers is becoming increasingly important in patient care and con-
sumer decision-making [6, 24, 25].
Social networks allow the exchange of healthcare information associated with symptoms, 
possible diagnosis, treatments, adverse side effects, and medical evidence, as well as opinions 
about experiences with healthcare providers [26]. More, this information can lead to inappro-
priate decisions due to limitations in consumer health literacy [24].
In the healthcare system, there are two sides, namely patient side and provider side, that 
connect with each other through common platforms [6, 26]. The provider side congregates 
all agents related to the healthcare system, such as healthcare professionals, pharmaceutical 
firms, medical technology firms, and all managers and other professional groups that have 
access to patient data, and for this reason are able to influence the healthcare systems [6]. The 
patient-side integrates the patients, their informal support structure, and everyone searching 
for healthcare information or support. To interconnect the two sides, digital platforms must 
exist, such as physician-patient appointments, health services provided by hospitals and com-
munities, organizations functioning as funding channels (e.g., Medicare), and other types of 
interactions between equipment/treatment providers and patients [26]. Some of these digital 
platforms support internal communication and information access, while others connect the 
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healthcare providers and patients and are relevant in the gatekeeping and mediation pro-
cesses, as well as providing information access [26].
Some social media functionalities are considered “Trojan horses” to the pharmaceutical indus-
try. Social media networks such as Twitter can present only part of what needs to be known 
by patients, due to character limits for shared content, which may cause errors. With this type 
of content limitation, marketers are challenged to find the right types of content to capture 
and persuade users regarding a firm value proposition [16]. Adding to this, most users tend 
to consider SNSs as social and non-commercial environments, thus the presence of advertis-
ing content on these platforms could be viewed by users as inappropriate or offensive [18].
Another important aspect that needs to be taken into account is the fact the content is no lon-
ger solely created by firms. Thus, firms may lose control over the content and need to consider 
the electronic word-of-mouth (e-WoM) phenomenon.
The rise of e-communication through social media is changing the healthcare and pharma-
ceutical industry [27]. Patients and providers are being empowered, since social media allows 
a greater control over the creation of content. All these empowered players can establish 
interactive connections with the pharmaceutical industry using social media as a communica-
tional channel, especially when pharmaceutical firms are considered trustworthy and present 
a value proposition that is perceived as positive by users [25]. Thus, social media platforms 
are acknowledged for providing wonderful opportunities for pharmaceutical marketers to 
interact with their customers and acquire knowledge of their markets [27, 28].
These social media platforms present a set of opportunities and threats for pharmaceutical 
marketers related to promotion and brand management. To better reach and engage users, 
they firstly need to learn from and follow up with users’ voices in order to tailor their mes-
sages to each individual or group. Thus, the content created and shared needs to be customer 
oriented and optimized for different scenarios, taking into consideration technological limits 
and regulations, while promoting brand awareness or notoriety [5]. Pharmaceutical firms can 
gather important brand monitoring data through social media platforms and also obtain criti-
cal information about consumers [13, 27]. These two resources enable pharmaceutical firms 
to develop innovative marketing strategies and services that could increase brand awareness, 
improve customer loyalty, and increase users’ trust and compliant behavior, while at the same 
time take advantage of the ability to promptly respond to information requests from differ-
ent users. One of the major threats posed by social media regards privacy and security, since 
content needs to always preserve patient-physician confidentiality, according to regulations.
Patient-side social media sites are becoming important information repositories, used to 
acquire health data from sources other than healthcare professionals. Still, the motivation to 
use these communication channels is wider, including monitoring health professionals’ deci-
sion-making, finding alternative treatments, predicting treatment results or consequences, 
and even self-diagnosis of minor symptoms [29]. There are several studies analyzing patient/
consumer use of three specific SNSs: Facebook, Twitter, and YouTube (Table 1).
The fast growth of social media that facilitates online social behavior has significantly mod-
ified the nature of human activities, habitats, and interactions [23]. Patients become more 
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active and empowered by the seamless access to information. Social media provides an open 
channel to all healthcare stakeholders [6], with different countries’ legal frameworks restrain-
ing or opening it, as a response to the public and policy concerns related to data privacy and 
security, as well as ethical behaviors.
Therefore, regardless of the main topic of research, the relevance of social media to the phar-
maceutical industry is evident, especially to those that are clearly focused on the consumer. 
Thus, it is no longer enough to consider the impact and role of digital communication at the 
firm and industry level; a closer look at social media interactions is now mandatory.
3. Top 20 pharmaceutical companies: empirical evidence on social 
media
Since the emergence of social media, pharmaceutical marketing academics and marketers 
have been intrigued by the influence of such media on their field. In this chapter, we argue 
that some of the research gaps, especially those related to barriers as well as reasons to use 
social media, are slowly being filled in by academic research as the industry starts to use 
social media with a more active posture. Thus, the current chapter explores the following two 
research questions: How is social media marketing being used by pharmaceutical companies? 
And what’s the influence of size and countries on social media activity?
In order to initiate this investigation, it was necessary to define the sample. As the subject of 
analysis was pharmaceutical companies’ presence on social media, the first important step was 
to choose the size of the sample. It was decided to use the top 20 pharmaceutical firms within 
a ranking of the top 50 in terms of revenue, as elaborated by Pharmaceutical Executive in 2013.
After defining the size of the sample, the social media presence of the top 20 pharmaceutical 
firms (on Facebook, Twitter, and YouTube) was analyzed by visiting their global homepage in 
order to search for evidence of their activity on social media. Two research coders retrieved 
Reference Unit of analysis Main research areas
Facebook Twitter YouTube
[29] x Information-driven patient use of SNSs
[25] x x Doctor-patient relationship
[24] x Content creation
[28] x Public health purposes
[30, 31] x Information source for patients living with chronic disease and 
their informal caregivers[32] x x
[33] x Education
Table 1. Some studies.
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Figure 2. Pharmaceutical firms analyzed in terms of social media presence.
the data in two distinctive periods (May 2016 and May 2017). This month was chosen due to 
the fact that worldwide a higher search rate is presented for medications driven by season 
conditions (e.g., spring and autumn allergies). When the homepage did not have a reference 
to social media presence, other official websites of the companies (e.g., websites of companies 
in specific countries) were visited and analyzed.
Figure 2 suggests that not all the pharmaceutical firms are present in the three major social 
media networks.
Of the companies examined, only 12 (60%) are on all social media platforms analyzed, while 
merely two (10%), namely Takeda and Daiichi-Sankyo pharmaceutical companies, are com-
pletely absent on such platforms.
An interesting finding is that Twitter is the SNS chosen by most companies, even though it has 
communication constraints regarding content length.
With all data collected, the next step was to calculate the engagement on each platform for each 
pharmaceutical company, using the following formula, later used in a cluster analysis (Table 2):
The engagement level was assessed by applying the formulas present in Table 3—Engagement 
formulas and the results are presented below:
From the table’s results, it can be inferred that Facebook engagement does not increase pro-
portionally with a firm’s revenue and number of employees, since Boehringer Ingelheim and 
Eli Lilly are the top performers in terms of engagement, in both periods. Similarly, Twitter 
engagement rates do not increase proportionally with the company size. However, one com-
pany (Teva) seems to have a high performance when compared to the other companies. The 
same result pattern was found on YouTube, where the size of the firm shows no correlation 
with the level of engagement achieved.
Looking at the activity of each SNS individually, starting with Facebook, two categories of 
posts were analyzed: (1) user posts and (2) brand posts. In terms of brand posts, all Facebook 
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pages analyzed had brand posts on their wall. The company which had the highest activ-
ity was Boehringer Ingelheim with 73 posts while the two companies with the lowest activ-
ity were Roche (Genentech) and AstraZeneca, both with 10 posts. Regarding user posts, only 
six Facebook pages (Merck & Co., Roche, Abbott, Bayer, Boehringer Ingelheim, and Novo 
Nordisk) had user posts on their wall, with each one having its own differentiated activity (see 
Figure 3). Moreover, all Facebook pages registered comment activity. Furthermore, the com-
pany which registered the largest amount of comments was Boehringer Ingelheim, with 1660 
comments, corresponding to 76% of all comments registered (in 2015). The figures for 2017 
were quite similar, showing slights increases.
The second biggest Facebook page in terms of comments was Roche, with 208 (10% of the 
comments), demonstrating a large difference between Boehringer Ingelheim and the other 
companies. In order to have a more precise analysis of the comments within brand posts, it 
was necessary to display the comments per brand post. Boehringer Ingelheim continues in 
front with a ratio of 22.74 (50%) comments in 2015 and with 32.22 in 2017; Roche continues in 
second place, but a third company, GlaxoSmithKline, emerges passing from 4.69 (10%) com-
ments in 2015 to 16.88 in 2017.
After analyzing the quantity of brand posts per company, a qualitative analysis of these posts 
was made. The majority of brand posts were in the format of the photo, totaling 59% posts in 
2014 and 48% in 2017. In second place are posts with links, with 24% posts in 2014 and 32% 
in 2017. The least frequent form of posting was in a form of status posts and video in 2014. In 
2017, video popularity increased, being used more (Figures 4 and 5).
This characterization reflects the performance of each cluster in each parameter, recognizing 
that these clusters are not homogeneous and therefore the companies included can have low 
and high performance in the same cluster (Table 4).
Table 2. Engagement formulas.
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Ranking Facebook Score 2015 Score 2017 Twitter Score 2015 Score 2017 Youtube Score 2015 Score 2017
1 Boehringer Ingelheim 0.078 0.102 Teva 18.17 19.65 Abbott 49.103 47.425
2 Eli Lilly 0.074 0.083 Eli Lilly 9.971 10.362 Astellas Pharma 17.842 21.31
3 Roche 0.041 0.042 Merck & Co. 4.84 4.73 Bayer 10.905 15.006
4 Merck & Co. 0.038 0.034 Roche (Genentech) 4.238 4.547 Novo Nordisk 9.352 9.352
5 Roche (Genentech) 0.038 0.038 Johnson & Johnson 3.252 4.382 Roche (Genentech) 7.699 7.344
6 Teva 0.025 0.025 Novo Nordisk 2.425 3.126 Amgen 4097 6.524
7 Sanofi 0.015 0.019 Boehringer Ingelheim 2.122 4.702 Pfizer 2.88 2.99
8 Novartis 0.015 0.015 Gilead Sciences 1.782 1.885 AstraZeneca 2.595 3.198
9 GlaxoSmithKline 0.013 0.096 Bristol-Myers Squibb 1.603 1.715 Sanofi 2.163 2.192
10 Novo Nordisk 0.009 0.009 Astellas Pharma 1.257 2.055 Boehringer Ingelheim 2.088 3.702
11 Pfizer 0.007 0.01 Novartis 1.253 1.589 Eli Lilly 2.039 2.003
12 Abbott 0.007 0.007 GlaxoSmithKline 1.13 1.02 Johnson & Johnson 1.523 1.578
13 Bayer 0.006 0.008 Abbott 0.984 1.114 GlaxoSmithKline 1.437 1.474
14 AstraZeneca 0.005 0.007 Roche 0.83 1.013 Merck & Co. 1.138 1.235
15 AstraZeneca 0.824 0.992 Novartis 1.033 1.564
16 Bayer 0.817 0.977 Roche 0.917 1.246
17 Sanofi 0.73 0.72
18 Pfizer 0.728 0.808
19 Amgen 0.64 0.764
20
Table 3. Digital engagement and firm size.
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With regard to Twitter, 18 of the 20 pharmaceutical firms were present. Notice, however, 
that Teva’s Twitter account is directed to the Spanish population, while the Astellas Pharma’s 
Twitter account is dedicated to the USA population.
Figure 4. Type of contents posted by brands. The results from the cluster analysis conducted shows four distinctive 
clusters.
Figure 3. Activity on Facebook.
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In order to have a clear view of the activity on Twitter, three important aspects were analyzed: 
(1) tweets, (2) retweets, and (3) mentions, which includes replies. Three companies have high 
activity (over 5000 tweets) since their Twitter account were opened, with Boehringer Ingelheim 
leading with 6940 (16%) tweets, followed by Johnson & Johnson 6069 (14%) tweets and Novartis 
5641 (13%) tweets. On the other hand, five companies registered less than 1000 lifetime tweets.
The customer service responses reflect the specific interaction between pharmaceutical firms and 
their twitter users’ requests. The company most active in this category was Johnson & Johnson 
Figure 5. Facebook clustering agglomeration.
Fan appreciators with 
high and low activity
Fan friendly with 
low to high activity
Strongly active fan 
haters
Non-active fan 
lovers
Revenue +++/−− ++/−− ++/− —
Employees ++/− +++/− ++/−− —
Brand posts +++/−− +/− ++/−− —
Brand post shares +++ ++/−− +/−−− +/−
Brand post likes ++ +/−− +/−−− ++
Brand post comments +++/− ++/− ++/−−− —
User posts +/−−− ++/− +/−−− +/−
Note: Each + sign reveals the positive intensity in each parameter while each – sign reveals the negative intensity in each 
parameter, because clusters are not homogeneous.
Table 4. Facebook clusters: characterization.
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with 48 customer service responses, corresponding to 48% of their total responses. Interestingly, 
the only company to maintain responses in less than 1 hour was Boehringer Ingelheim during 
the period of analysis.
When analyzing the pharmaceutical companies’ presence on Twitter through a cluster analy-
sis, five clusters were identified (Figure 6).
After the first set of analysis, a deep analysis of the network structure of Twitter was con-
ducted with the most recent data, using the NodeXL software, for the biggest and for the most 
engaging companies, aiming to establish their network structure and assess if it was linked to 
specific countries. The HK fast multiscale layout algorithm shows a pseudo-random network 
with five clusters in the case of Pfizer. Each cluster is linked to a specific country, with USA 
users the most active on the network (Figure 7).
Boehringer Ingelheim presents a quite uniquely structured network, denoting less spontane-
ous content creation and less community dispersion by country. The most relevant node is the 
company node. USA users are the most active on the network (31%), followed by UK users 
(16%), and Spanish users (9%).
The analysis of pharmaceutical presence on YouTube revealed that 15 companies have a 
YouTube Channel. The subscribers are an important part of the activity of YouTube chan-
nels because they receive notifications for each new video. One remarkable standout in the 
subscriber analysis is the dominance of Johnson & Johnson, registering the highest number 
of subscribers, while the second biggest company is Amgen. Johnson & Johnson outperforms 
in this category with 58% of the total number of views registered. Pharmaceutical companies’ 
Figure 6. Twitter cluster analysis.
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YouTube channels were also subjected to a cluster analysis identical to the ones performed for 
Facebook and Twitter (Figure 8).
The Japanese companies Takeda and Daiichi-Sankyo have completely abandoned the three 
assessed platforms, while Astellas is not in the same situation because Astellas USA possesses 
a Twitter account and a YouTube channel. YouTube appears to be the most abandoned social 
media platform, even though the use of video contents increased.
Figure 8. YouTube cluster analysis.
Figure 7. Network graphs obtained using the Harel-Koren Fast Multiscale layout. Legend: blue—USA, red—Greece, 
green—Germany.
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4. Final considerations
Over the last 15 years, social media took over the online world, connecting more people, 
firms, and brands. However, there are a number of industries that are still lacking in social 
media exposure and interaction with customers. The question that remains unanswered 
is what leads to a greater investment in social media by films and in which social media?
In the pharmaceutical industry, social media is a tool that is used to communicate with con-
sumers. However, not all pharmaceutical firms have a Facebook page, Twitter account, or 
YouTube channel. In fact, only a small number of the pharmaceutical firms analyzed utilize 
the three social media platforms simultaneously. Also, it seems that smaller pharmaceutical 
firms are leaving some social media platforms. These observations could be a result of an 
absence of official guidance in the use of such platforms associated with difficulty to calculate 
return on investment in the same platforms.
The analysis of the activity of pharmaceutical firms on social media revealed that in the several 
parameters studied for each social media platform there were diverse sets of scenarios, with 
some companies performing better than others in one parameter but with a poor performance 
in others. Also, some companies appeared almost inactive on such platforms. Moreover, 
when analyzing the ultimate indicator of activity (engagement raking), smaller companies 
lead the ranking. However, there is not an association between good performance in this 
ranking with the size of the companies, in terms of revenue and employees. This suggests that 
other factors could influence digital engagement and therefore, should be evaluated in future 
research. Regarding digital engagement strategy, pharmaceutical firms do not use the same 
strategy between the three social media platforms analyzed and have evolved between 2014 
and 2017. The cluster analysis showed that in general pharmaceutical firms behave differently 
on Facebook, Twitter, and YouTube. As their distribution in clusters/segments demonstrated, 
they present different characteristics among these platforms. However, it seems that Eli Lilly 
shares some similarities between Facebook and Twitter digital engagement strategy.
The multifaceted communication in the virtual world has recognized consequences besides 
its connectivity benefits. Pharmaceutical firms are challenged to adopt an increasing digital 
presence, following major social media trends. Therefore, this work is a small step toward 
understanding the full potential of social media in this sector, and it leaves an invitation to 
future research.
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